Eylea Post Marketing Surveillance(PMS)
NCT01783925 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3206
Last updated 2023-11-07
Summary
The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by MFDS
Conditions
- Macular Degeneration
Interventions
- DRUG
-
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-04-29
- Primary Completion
- 2018-12-31
- Completion
- 2018-12-31
Countries
- South Korea
More Related Trials
-
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept
NCT02615496 ·Status: COMPLETED
-
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
NCT02585401 ·Status: COMPLETED
-
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
NCT02581891 ·Status: COMPLETED ·Phase: PHASE4
-
To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
NCT02540369 ·Status: COMPLETED
-
Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
NCT02279537 ·Status: COMPLETED
-
Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann
NCT04891835 ·Status: COMPLETED
-
Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
NCT02125864 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
NCT05275205 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
NCT02821247 ·Status: COMPLETED
-
Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
NCT01914380 ·Status: COMPLETED
-
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
NCT04641234 ·Status: COMPLETED
-
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT03411941 ·Status: COMPLETED
-
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
NCT00964795 ·Status: COMPLETED ·Phase: PHASE3
-
Aflibercept in Polypoidal Choroidal Vasculopathy
NCT02120950 ·Status: COMPLETED ·Phase: PHASE4
-
Intravitreal Aflibercept for Submacular Hemorrhage
NCT03169660 ·Status: COMPLETED ·Phase: PHASE4
-
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
NCT02541084 ·Status: COMPLETED
-
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
NCT01521559 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04423718 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
NCT03382587 ·Status: COMPLETED
-
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
NCT03610646 ·Status: COMPLETED ·Phase: PHASE3
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
NCT00509795 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
NCT02818998 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT04450329 ·Status: COMPLETED ·Phase: PHASE3
-
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
NCT03278262 ·Status: COMPLETED
-
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
NCT05587062 ·Status: COMPLETED ·Phase: PHASE3